Hermetica Superfood Encyclopedia
Legacy index-continuity record: the score and narrative are provisional and must not be represented as validated or human-approved.
Review flags: AWAITING_SEMANTIC_VALIDATION
Lactobacillus reuteri DSM 17938 is a clinically studied probiotic strain that produces reuterin, an antimicrobial compound that helps balance gut microbiota. This strain modulates immune function through toll-like receptor signaling and supports digestive health by enhancing intestinal barrier integrity.
Reported Benefits (Provisional)
Origin & History
Lactobacillus reuteri DSM 17938 is a probiotic strain derived from the human gut microbiota. It is cultured through fermentation and is used in dietary supplements and functional foods.
Research Narrative (Provisional)
Lactobacillus reuteri DSM 17938 has been studied in multiple RCTs, showing efficacy in supporting digestive and immune health. Meta-analyses confirm its benefits in various health conditions.
Preparation & Dosage
Dosage guidance is withheld because the publication gate has not recorded adequate support for this profile.
Nutritional Profile
- Contains live probiotic cultures. - Produces lactic acid, supporting gut health. - Rich in bioactive compounds that modulate the immune system.
Reported Mechanism (Provisional)
Lactobacillus reuteri DSM 17938 produces reuterin (3-hydroxypropionaldehyde) from glycerol, which exhibits broad-spectrum antimicrobial activity against pathogenic bacteria while preserving beneficial microbes. The strain activates toll-like receptors (TLR2/TLR4) on intestinal epithelial cells, triggering anti-inflammatory cytokine production including IL-10. It also strengthens tight junction proteins like claudin-1 and occludin, improving intestinal barrier function and reducing inflammatory responses.
Clinical Narrative (Provisional)
Multiple randomized controlled trials have demonstrated the efficacy of L. reuteri DSM 17938, particularly in pediatric populations. Studies with 50-400 participants show significant reduction in infantile colic crying time by 50-80% within 21 days of supplementation. Adult trials (n=100-200) demonstrate improved digestive symptoms and reduced inflammatory markers after 4-8 weeks of daily administration. The evidence is strongest for gastrointestinal applications, with emerging research on immune and neurological benefits showing promising but preliminary results.
Also Known As
Research updates — and 25% off your first order
Join our list for source-aware wellness education, review-state updates, and product news — and unlock 25% off your first Hermetica order. Educational content is not medical advice. No spam, unsubscribe anytime.